

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: S. K. Davidsen, et al.

Serial No.: Continuation of prior application No.  
09/239,087, Examiner: R. Gerstl, Group /Art Unit  
1626

File No. of prior application: 6162.US.P1

Filed: January 27, 1999

For: REVERSE HYDROXAMATE INHIBITORS  
OF MATRIX METALLOPROTEINASES

Case No.: 6162.US.C1

Date: July 11, 2001

**Certificate of Mailing under 37 CFR §1.8(a):**

I hereby certify that this paper (along with any  
paper referred to as being attached or enclosed) is  
being deposited with the United States Postal  
Service with sufficient postage as First Class Mail  
addressed to:

**Box DAC**

Assistant Commissioner for Patents  
Washington, D.C. 20231

on July 12, 2001

Name of person signing  
this certificate: Laura S. Niemietz

Signature:

*Laura S. Niemietz*

**PRELIMINARY AMENDMENT**

Director of Patents and Trademarks

Washington, D.C. 20231

Dear Sir:

Applicants request entry of the following amendment and reconsideration of the  
subject application in view of the following remarks. Applicants have also submitted  
herewith a Petition for Revival of an Application For Patent Abandoned Unintentionally.

**IN THE SPECIFICATION**

Directly beneath the title, please insert the following sentence:

This application is a continuation of U.S. Application Ser. No. 09/239,087, filed  
January 27, 1999.

**IN THE CLAIMS**

Please replace Claims 14 and 21 with the correspondingly numbered claims.

14 (Amended). A compound according to claim 23 selected from the group consisting of

*N*-[4-[4-[[4-chlorophenoxy]phenyl]sulfonyl]methyl]tetrahydro-2H-pyran-4-yl]-*N*-hydroxyformamide and

*N*-[4-[4-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]tetrahydro-2H-pyran-4-yl]-*N*-hydroxyformamide.

21 (Amended). A compound according to claim 23 which is [S-(R\*,R\*)]-*N*-[1-(2,2-dimethyl-1,3-dioxol-4-yl)-2-[[4-[4-(trifluoromethoxy)-phenoxy]phenyl]sulfonyl]ethyl]-*N*-hydroxyformamide.

Please add the following new claims:

23 (New). A compound according to Claim 7 wherein X is -S(O)<sub>p</sub>-; and R<sub>2</sub> is hydroxyalkyl or heterocycle.

24 (New). A compound according to Claim 23 wherein Y is a covalent bond, -O-, or -S(O)<sub>p</sub>-; and Ar<sub>2</sub> is phenyl wherein the phenyl can be optionally substituted.

25 (New). A compound according to Claim 24 which is [S-(R\*,R\*)]-*N*-hydroxy-*N*-[(2,3-dihydroxy)-1-[[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]methyl]propyl]-*N*-hydroxyformamide.

26 (New). A compound according to Claim 13 wherein X is -S(O)<sub>p</sub>-; Y is a covalent bond, -O-, or -S(O)<sub>p</sub>-; and Ar<sup>1</sup> and Ar<sup>2</sup> are phenyl wherein the phenyl can be optionally substituted.

#### REMARKS

Claims 1-17, 19-22 were pending. After entry of the above amendment, Claims 1-17 and 19-26 will be pending.

The amendment accompanying these remarks amends Claims 14 and 21 and adds New Claims 23-26.

Support for New Claims 23, 24, and 26 can be found in the claims as originally presented and from page 2, line 1 to page 10 line 21 of the specification.

Support for New Claim 25 is found on page 24, lines 13-15 and on pages 127 and 128, lines 12-30 and 1-9, respectively, of the specification.

### **Double Patenting Rejections**

Claims 1-13, 15-17, and 19-22 stand provisionally rejected as being unpatentable over Claims 1-13, 15, 17, and 18 of copending Application No. 09/492,567 and over Claims 1-13, 15, 17, and 18 of copending Application No. 09/492,718.

Applicants will file a Terminal Disclaimer, pursuant to 37 CFR §§ 1.321, for copending Application Nos. 09/492,567 and 09/492,718.

Claim 14 stands provisionally rejected as being unpatentable over Claim 14 of copending Application No. 09/492,567. The Examiner required cancellation of the conflicting claims from all but one application or maintenance of a clear line of demarcation between the applications.

Claims 14 and 18 stand provisionally rejected as being unpatentable over Claim 14 and 16 of copending Application No. 09/492,718. The Examiner required cancellation of the conflicting claims from all but one application or maintenance of a clear line of demarcation between the applications.

Applicants will amend the claims in copending Application Nos. 09/492,567 and 09/492,718 to maintain of a clear line of demarcation between the claims therein and the instant claims.

Because Application No. 09/492,567 will have a clear line of demarcation between the claims therein and the instant claims and Application Nos. 09/492,567 and 09/492,718 will have the same pendency as the instant application, the double patenting rejection has been rendered moot, and withdrawal of the rejection is respectfully requested. Applicants would be pleased to supply confirmation of the Terminal Disclaimer and cancellation of the claims in the copending applications upon the Examiner's request.


### **Conclusion**

Accordingly, in view of the above, Applicants respectfully request reconsideration and allowance of claims 1-17 and 19-26.

The Director is hereby authorized to charge any additional fees required under 37 C.F.R. §§ 1.16 concerning this transaction or to credit any overpayment to Deposit Account No. 01-0025.

Respectfully submitted,  
Abbott Laboratories  
Dept. 377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL 60064-6050  
Tel. No. (847) 937-3810  
Fax No. (847) 938-2623

S. K. Davidsen, et al.

  
B. Gregory Donner  
Registration No. 34,580  
Agent for Applicant(s)

0905242.071501